These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 15022281)
1. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Zang RY; Li ZT; Tang J; Cheng X; Cai SM; Zhang ZY; Teng NN Cancer; 2004 Mar; 100(6):1152-61. PubMed ID: 15022281 [TBL] [Abstract][Full Text] [Related]
2. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030 [TBL] [Abstract][Full Text] [Related]
3. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412 [TBL] [Abstract][Full Text] [Related]
4. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441 [TBL] [Abstract][Full Text] [Related]
5. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649 [TBL] [Abstract][Full Text] [Related]
6. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy. Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820 [TBL] [Abstract][Full Text] [Related]
7. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ; Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163 [TBL] [Abstract][Full Text] [Related]
8. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056 [TBL] [Abstract][Full Text] [Related]
9. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Eisenkop SM; Friedman RL; Wang HJ Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815 [TBL] [Abstract][Full Text] [Related]
10. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma]. Zang R; Zhang Z; Cai S Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017 [TBL] [Abstract][Full Text] [Related]
12. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277 [TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of secondary cytoreductive surgery for recurrent advanced ovarian cancer]. Zang R; Zhang Z; Cai S Zhonghua Zhong Liu Za Zhi; 2002 Mar; 24(2):194-6. PubMed ID: 12015048 [TBL] [Abstract][Full Text] [Related]
14. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer. Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459 [TBL] [Abstract][Full Text] [Related]
15. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096 [TBL] [Abstract][Full Text] [Related]
16. Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer. Park JY; Eom JM; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH J Surg Oncol; 2010 Apr; 101(5):418-24. PubMed ID: 20082350 [TBL] [Abstract][Full Text] [Related]
17. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M; Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206 [TBL] [Abstract][Full Text] [Related]
18. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC). Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175 [TBL] [Abstract][Full Text] [Related]
19. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603 [TBL] [Abstract][Full Text] [Related]